Robert J. Fram - Take | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P2.10-15 Correlation Between Clinical and Health-related Quality-of-Life (hrqol) Benefits in Patients with ALK+ NSCLC in ALTA-1L

R. García-Campelo,H.M. Lin,M. Pérol,M. Jahanzeb,A. Szumski, Y. Wu, A. Geiger,E. Goodman,R.J. Fram,S. Popat,D.R. Camidge

Journal of Thoracic Oncology（2023）

引用0浏览0引用

EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/ metastatic NSCLC

P. A. Janne,B-C. Wang,B. C. Cho, J. Zhao, J. Li,M. J. Hochmair, S. Peters, B. Besse, T. Kato,Y-L. Wu, D. Nguyen, J. Lin, J. Lin,F. Vranceanu, M. Lin,R. J. Fram,T. S. K. Mok

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment

C. Zhou, B. Li, J. Fang, J. Zhou, Y. Hu, C. Zhu,V. Bunn, M. Lin,J-L. Hong,J. Huang, J. Wang,R. J. Fram, S. Vincent, Y. Li

ANNALS OF ONCOLOGY (2023): S1699-S1699

引用0浏览0引用

ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+NSCLC

S. Chatterjee,X. Tong,Z. Su, Y. Li,M. Guha,E. N. Churchill,R. J. Fram,S. Vincent

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S255-S255

引用0浏览0引用

Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK plus NSCLC in ALTA-1L

R. Garcia-Campelo,H. M. Lin,M. Perol,M. Jahanzeb,A. Szumski, Y. Wu, A. Geiger,E. Goodman,R. J. Fram,S. Popat,D. R. Camidge

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S358-S359

引用0浏览0引用

P1.23-01 ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC

S. Chatterjee,X. Tong,Z. Su, Y. Li,M. Guha,E.N. Churchill,R.J. Fram,S. Vincent

Journal of Thoracic Oncologyno. 11 (2023): S255-S255

引用0浏览0引用

Subasumstat, a First-in-class Inhibitor of SUMO-activating Enzyme, Demonstrates Dose-Dependent Target Engagement and SUMOylation Inhibition, Leading to Rapid Activation of Innate and Adaptive Immune Responses in the Dose Escalation Portion of a Phase 1/2 Clinical Study

G. Saggu, D. Stroopinsky,A. Z. Dudek,A. J. Olszanski,D. Juric,A. Dowlati,U. Vaishampayan, H. Assad,J. Rodon, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi,A. Gomez-Pinillos,R. J. Fram, A. Berger,K. Sachsenmeier, S. Kasar

European journal of cancer（2022）

引用0浏览0引用

239 Niraparib, a Selective PARP 1/2 Inhibitor, is Efficacious in Pre-Clinical Models of Small-Cell Lung Cancer

Y. Wang,J. Ricono, K. Admunson,S. Agarwal,R. J. Fram,T. Broudy,K. M. Wilcoxen

European journal of cancer (2014): 80-81

引用0浏览0引用

XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development

A. V. Yurkovetskiy,R. J. Fram

Current bioactive compounds（2011）

引用5浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn